Literature DB >> 6615664

Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.

A D Struthers, R Whitesmith, J L Reid.   

Abstract

To simulate increased sympathoadrenal activity adrenaline was infused in normotensive subjects to achieve plasma adrenaline concentrations similar to those seen after myocardial infarction or hypoglycaemia. Adrenaline was infused after pretreatment for five days with labetalol 200 mg twice daily or placebo given in a random order. The rise in systolic blood pressure and the fall in diastolic blood pressure observed after the infusion of adrenaline (0.06 micrograms/kg/min) were prevented by labetalol and no increase in blood pressure was seen. Adrenaline infusion after pretreatment with placebo caused a profound fall in the serum potassium concentration (4.12-3.20 mmol(mEq)/l). Pretreatment with labetalol completely blocked adrenaline induced hypokalaemia (3.92-3.95 mmol(mEq)/l). Adrenaline induced T wave flattening and QTc prolongation were also prevented by labetalol. Thus labetalol can prevent the electrocardiographic, haemodynamic, and hypokalaemic effects of increased circulating adrenaline in man. The combination of alpha and beta blockade appears to be required to block the haemodynamic effects of adrenaline, and labetalol may, therefore, be useful in controlling both the metabolic and circulatory responses during increased sympathoadrenal activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615664      PMCID: PMC481409          DOI: 10.1136/hrt.50.3.277

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  16 in total

Review 1.  Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system.

Authors:  P E Cryer
Journal:  N Engl J Med       Date:  1980-08-21       Impact factor: 91.245

2.  Alpha-adrenoceptor-mediated coronary artery spasm.

Authors:  D L Levene; M R Freeman
Journal:  JAMA       Date:  1976-08-30       Impact factor: 56.272

3.  Circulatory effects of noradrenaline and adrenaline before and after labetalol.

Authors:  D A Richards; B N Prichard; R Hernández
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

4.  Propranolol block of epinephrine-induced hypokaliaemia in man.

Authors:  F Massara; A Tripodina; M Rotunno
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

Review 5.  Clinical pharmacology of labetalol.

Authors:  D A Richards; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

6.  Reduction of enzyme levels by propranolol after acute myocardial infarction.

Authors:  T Peter; R M Norris; E D Clarke; M K Heng; B N Singh; B Williams; D R Howell; P K Ambler
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

7.  Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle.

Authors:  T Clausen; J A Flatman
Journal:  Br J Pharmacol       Date:  1980-04       Impact factor: 8.739

Review 8.  Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.

Authors:  D T Mason
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

9.  Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.

Authors:  R A Rizza; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram.

Authors:  D R Ricci; A E Orlick; P R Cipriano; D F Guthaner; D C Harrison
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

View more
  5 in total

1.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Effect of CGP 17/582, a selective beta-adrenoceptor antagonist, on the haemodynamic and hypokalaemic response to adrenaline.

Authors:  K F Whyte; P J De Vane; R Whitesmith; A Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Effects of atenolol and pindolol on the hypokalaemic and cardiovascular responses to adrenaline infusion.

Authors:  K Forfang; S Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects.

Authors:  Tomi Laitinen; Tiina Lyyra-Laitinen; Hanna Huopio; Ilkka Vauhkonen; Toivo Halonen; Juha Hartikainen; Leo Niskanen; Markku Laakso
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

Review 5.  Combined receptor intervention and myocardial infarction.

Authors:  D A Chamberlain; R Vincent
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.